摘要
目的:探讨中性粒细胞/淋巴细胞比值(NLR)在冠状动脉粥样硬化性心脏病(CAD)三支病变患者经皮冠状动脉介入术(PCI)术后预后评估中的价值。方法:回顾性收集2019年6月1日至2023年10月31日郑州大学第一附属医院收治并接受PCI的CAD三支病变患者的临床资料,根据NLR中位数分为高NLR组(n=209)和低NLR组(n=208),绘制Kaplan-Meier风险曲线,采用Cox回归分析NLR与不良结局的关系。结果:在完全调整模型中,NLR对于全因性死亡和主要不良心血管事件的HR(95%CI)分别为1.057(1.021~1.092)和1.031(1.004~1.055),而高NLR组的HR(95%CI)分别为2.730(1.244~6.009)和1.883(1.171~3.033)。NLR对于全因性死亡和主要不良心血管事件的曲线下面积(95%CI)、敏感度、特异度分别为0.823(0.782~0.863)、0.886、0.312和0.750(0.658~0.842)、0.692、0.324,具有良好的预测价值。结论:NLR可作为CAD三支病变患者PCI术后预后的可靠预测指标。
Aim:To explore the clinical value of neutrophil-to-lymphocyte ratio(NLR)in predicting the prognosis of patients with triple-vessel coronary artery disease(CAD).Methods:This study retrospectively collected clinical data of patients with triple-vessel CAD who accepted percutaneous coronary intervention(PCI)at the First Affiliated Hospital of Zhengzhou University from June 1,2019,to October 31,2023.Based on the median NLR,patients were allocated into high NLR group(n=209)and low NLR group(n=208),and baseline characteristics were compared between the groups.Kaplan-Meier risk curves were drawn.Cox regression analysis was used to analyze the relation between NLR and adverse outcomes.Results:In the fully adjusted model,HR(95%CI)of NLR for all-cause mortality(ACM)and major adverse cardiovascular event(MACE)was 1.057(1.021-1.092)and 1.031(1.004-1.055),respectively.In the high NLR group,HR(95%CI)for ACM and MACE were 2.730(1.244-6.009)and 1.883(1.171-3.033),respectively.The area under the curve(95%CI)for NLR was 0.823(0.782-0.863),sensitivity of 0.886,specificity of 0.312 for ACM and 0.750(0.658-0.842),sensitivity of 0.692,specificity of 0.324 for MACE,indicating good predicting value.Conclusion:NLR could be considered a reliable prognostic indicator for patients with triple-vessel CAD undergoing PCI.
作者
朱揆
沈德新
赵江涛
秦奋
陈晓伟
于凤仪
吕炎
杨宇
秦臻
高佳敏
陶海龙
唐俊楠
ZHU Kui;SHEN Dexin;ZHAO Jiangtao;QIN Fen;CHEN Xiaowei;YU Fengyi;LYU Yan;YANG Yu;QIN Zhen;GAO Jiamin;TAO Hailong;TANG Junnan(Department of Cardiology,the First Affiliated Hospital,Zhengzhou University,Henan Province′s Key Laboratory of Cardiac Injury and Repair,Henan Cardiovascular Disease Clinical Medical Research Center,Zhengzhou 450052;Department of Pediatrics,Joint Logistics Force No.988 Hospital of the PLA,Zhengzhou 450007)
出处
《郑州大学学报（医学版）》
CAS
北大核心
2024年第5期673-677,共5页
Journal of Zhengzhou University(Medical Sciences)
基金
河南省重点研发与推广专项(222102310189)
河南省科技研发计划联合基金项目(优势学科培育项目)(222301420054)。
